Open in interactive viewer → charts, metric popovers & call review

CapsoVision Cleared Its AI and Immediately Got Billed for Memory

A September FDA clearance, a year-end colon submission and $18 million of fresh capital — undercut by a flash-memory price spike that has nothing to do with endoscopy.
CV · Earnings Call · 2026-11-12

What Actually Changed

The headline numbers from CapsoVision's third quarter look almost frozen: revenue of $3.6 million against $3.5 million a year ago, 8,464 CapsoCam Plus capsules shipped versus 8,336, and an average selling price management described as "stable year-over-year." That is a 1% business. What changed is regulatory and it happened after the quarter closed — AI Highlights for CapsoCam Plus won FDA clearance on September 25 and launched commercially in the U.S. on November 2, ten days before this call. That timing matters enormously. The entire commercial thesis now sits on a product that had eleven days of U.S. selling days behind it at the moment of the print. Management did not pretend otherwise: “With the AI Highlights launched earlier this month, we expect sales of CapsoCam Plus to accelerate with the full impact realized in 2027.” — David Garcia, Senior Vice President of Finance · 2026-11-12 Read that plainly: 2026 is already spoken for. The stock is now a 2027 revenue option trading at a $334 million market cap. The clinical case for the module is unusually specific for a small-cap medtech launch. Doug Atkinson relayed a physician who read the same study twice: without AI, “he missed 2 AVMs, 2 critical areas of pathology that he thought it was a normal study. And then when he read it with AI, it did capture 2 AVMs” — Douglas Atkinson, Senior Vice President · 2026-11-12 — arteriovenous malformations. The sellable claims are reading time, accurate review, and diagnostic confidence, layered on the 4-camera 360-degree panoramic view in small bowel imaging, plus a pediatric indication down to age two. That is a genuinely differentiated bundle; no other small-bowel capsule pairs panoramic imaging with cleared AI review.

A Memory Tax on a Capsule Company

Here is where the quarter gets interesting, and not in a good way. Gross margin fell to 49% from 54%. The cause was not price. “Gross margin in the quarter was impacted by higher material costs due to increasing prices of flash memory, a onetime charge for inventory obsolescence and higher stock-based compensation expense.” — David Garcia, Senior Vice President of Finance · 2026-11-12 A single-use camera pill is, functionally, a disposable imaging computer with a radio — and it eats flash memory. That makes a sub-$400 million endoscopy company a price-taker on a commodity set by hyperscaler AI demand. The global keyword record shows this theme is not idiosyncratic: memory pricing and memory cost have been recurring market keywords through 2026, and high bandwidth flash was one of the strongest 12-month movers in the whole market tape before cooling over the last 90 days. This week alone, audio hardware maker Sonos flagged a "memory cost impact" measured in basis points of margin. Same tax, different product. The uncomfortable wrinkle: memory equities have de-rated over the last 30 days while the price CapsoVision pays for components lags. Cost relief, if it comes, arrives quarters after the equity market prices it. Meanwhile the company's own margin shape has been eroding for two years — gross margin down about five points from its 2024 peak of 56% — and the September quarter marks a further step below that trajectory. Five points of margin is roughly $180,000 a quarter at this revenue base, trivial against a $7.3 million net loss. But it is the wrong vector precisely when the story requires margin to help fund a sales push.

The Colon Option, Priced on Faith

The larger prize is CapsoCam Colon. Enrollment and data collection are complete, including physician reads with and without AI assistance, and the FDA submission is still expected before year-end 2026. Management sizes the near-term U.S. opportunity at roughly $1 billion — patients at high risk for colonoscopy or with an incomplete procedure — with a longer-term market above $10 billion as screening guidelines push down to age 45. The evasiveness is here, and it is worth flagging. Asked when the pivotal data would be shown publicly, Johnny Wang gave a two-part answer that promised the number and withheld the disclosure: “we are confident that data will be available next month. But whether to share it publicly, we would like to have an internal meeting with Doug and Dave as well as we also want to touch base with our legal counsel.” — Kang Wang, President and Chief Executive Officer · 2026-11-12 For a company whose equity value now rests on a single readout, "we'll discuss internally whether to tell you" is a soft tell. Note also that the same regulatory demographic-analysis question that hung over the AI clearance last quarter remains the untested risk on the colon filing.

What Stopped Being Said

Last quarter, an analyst asked point-blank about pricing pressure and tariffs. Dave Garcia's reply was direct: “we do have one particular competitor that we go up against, and we just see that pressure and that impacted us a little bit in the quarter.” — David Garcia, Senior Vice President of Finance · 2026-08-13 The phrase pricing pressure was among the company's most prominent themes that quarter. This quarter the same force reappears wearing a suit: “The third quarter reflected a competitive pricing environment in the U.S. for small bowel capsule endoscopy even as we continue to make progress in expanding our customer base.” — David Garcia, Senior Vice President of Finance · 2026-11-12 The threat got renamed, not resolved — though ASP stability suggests CapsoVision is currently absorbing it rather than conceding price. That is exactly the strategy the CEO pre-announced in August:

in order to keep this price, keep the margin, I think one of the things we need to do is to increase the value of our system, right? To -- by launching the AI in the U.S., this should help with the increase the value of our offering, okay?

Kang Wang, President and Chief Executive Officer · 2026-08-13
So AI Highlights is not merely a product; it is the price umbrella. Whether it holds is the single most important thing to watch in 2027. The other structural shift is customer mix. Atkinson put it at roughly 65% GI clinic and 35% hospital system, with hospitals growing fast off a base of 34 new accounts added in the quarter — 9 hospital systems, 4 pediatric clinics, 21 adult GI clinics — and 184,000 cumulative patients, up from 151,000.

The Balance Sheet and the Tape

CapsoVision raised $17.8 million net through an registered direct offering in mid-September and another $1.7 million selling 276,446 shares into its ATM, ending with $21.8 million in cash. Management said only that this "extends our expected cash runway" — no number. Against roughly $9 million of quarterly free cash burn, that is a runway measured in quarters, not years, which is why the ATM language was left deliberately open. The spend profile is barbell-shaped: R&D running well above total revenue, while opex is being squeezed downward now that the pivotal study is done. And the tape is telling its own story. The stock is 65 sessions old, down 6.7% over that window, having peaked at $7.06 on October 28 — one day before FDA clearance was announced — and now sits 14.6% off that high. This is a classic sell-the-clearance, question-the-launch pattern: the market paid for the catalyst and is now waiting on evidence that it converts into units. Revenue will not confirm anything until 2027, gross margin is moving the wrong way for reasons entirely outside management's control, and the biggest asset in the company is a data readout management has not yet committed to publishing.